These findings highlight the utility of CRISPR-Cas9 in uncovering the metabolic mechanisms driving aryl hydrocarbon receptor (AhR) dependent and PAH-induced developmental toxicity (Rude et al., 2024). The gene discussed is AHR; the disease is pulmonary arterial hypertension.